

International Union of Operating Engineers Welfare Fund of Eastern Pennsylvania and Delaware

1375 VIRGINIA DRIVE, SUITE 102
FORT WASHINGTON, PENNSYLVANIA 19034
Phone: (215) 542-8211 Fax: (215) 540-9369

JOHN HEENAN, Administrator



SUMMARY OF MATERIAL MODIFICATIONS

(Please keep this insert with your Welfare Fund Summary Plan Description)

Beginning April 1, 2023, the Welfare Fund began partnering with HealthSmartRx Solutions to reduce the cost of certain specialty prescriptions through HealthSmart Rx's Smart RxAssist Program. The Program allows the Welfare Fund to access co-pay assistance programs offered by drug manufacturers.

To receive certain specialty drugs under the Welfare Fund, you must first contact the Program and fully cooperate with its efforts to secure the prescription and access any co-pay assistance. If you have a specialty drug prescription, please call 1-833-800-4037. The list of specialty drugs subject to the Program can be found here: www.IUOE542funds.com/welfare

Your co-pay will vary, depending on the assistance that the Program is able to find, and the amount that the manufacturer requires you to pay. If the Program is not able to find co-pay assistance, your specialty drug prescription benefits will be determined in accordance with the Welfare Fund's regular prescription drug rules.

Please be aware that any co-pay assistance that the Program can secure will not count toward your deductible or out-of-pocket maximum for the year, although your actual co-pays will count towards that maximum. If you are required to pay a co-pay for a specialty drug through the Program and have already met your out-of-pocket maximum for the year, the Welfare Fund will reimburse you for the co-pay. If a drug manufacturer pays you directly as part of any co-pay assistance, and the Welfare Fund has already paid for the specialty drug, you are required to reimburse the Welfare Fund.

Using the Program to obtain a specialty drug does not constitute a claim for benefits under the Welfare Fund's claim procedures.

Please review this language carefully.

Should you have any questions with respect to these revisions, please contact the Fund Office.

Issued: March 2023